AbbVie prices new rheumatoid arthritis drug at $59,000/yr

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

AbbVie prices new rheumatoid arthritis drug at $59,000/yr

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, ...

Fri 16 Aug 19 from Reuters

FDA approves AbbVie's new rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship ...

Fri 16 Aug 19 from Reuters Health

  • Pages: 1

Bookmark

Bookmark and Share